{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:41:58Z","timestamp":1792651318505,"version":"4.5.0"},"reference-count":406,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T00:00:00Z","timestamp":1649376000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>All endocrine glands are susceptible to neoplastic growth, yet the health consequences of these neoplasms differ between endocrine tissues. Pituitary neoplasms are highly prevalent and overwhelmingly benign, exhibiting a spectrum of diverse behaviors and impact on health. To understand the clinical biology of these common yet often innocuous neoplasms, we review pituitary physiology and adenoma epidemiology, pathophysiology, behavior, and clinical consequences. The anterior pituitary develops in response to a range of complex brain signals integrating with intrinsic ectodermal cell transcriptional events that together determine gland growth, cell type differentiation, and hormonal production, in turn maintaining optimal endocrine health. Pituitary adenomas occur in 10% of the population; however, the overwhelming majority remain harmless during life. Triggered by somatic or germline mutations, disease-causing adenomas manifest pathogenic mechanisms that disrupt intrapituitary signaling to promote benign cell proliferation associated with chromosomal instability. Cellular senescence acts as a mechanistic buffer protecting against malignant transformation, an extremely rare event. It is estimated that fewer than one-thousandth of all pituitary adenomas cause clinically significant disease. Adenomas variably and adversely affect morbidity and mortality depending on cell type, hormone secretory activity, and growth behavior. For most clinically apparent adenomas, multimodal therapy controlling hormone secretion and adenoma growth lead to improved quality of life and normalized mortality. The clinical biology of pituitary adenomas, and particularly their benign nature, stands in marked contrast to other tumors of the endocrine system, such as thyroid and neuroendocrine tumors.<\/jats:p>","DOI":"10.1210\/endrev\/bnac010","type":"journal-article","created":{"date-parts":[[2022,4,8]],"date-time":"2022-04-08T13:01:51Z","timestamp":1649422911000},"page":"1003-1037","source":"Crossref","is-referenced-by-count":327,"title":["Clinical Biology of the Pituitary Adenoma"],"prefix":"10.1210","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2355-3447","authenticated-orcid":false,"given":"Shlomo","family":"Melmed","sequence":"first","affiliation":[{"name":"Cedars-Sinai Medical Center , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula B","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Brigham & Women\u2019s Hospital and Harvard Medical School , Boston, MA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8661-6727","authenticated-orcid":false,"given":"M Beatriz","family":"Lopes","sequence":"additional","affiliation":[{"name":"University of Virginia School of Medicine , Charlottesville, VA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerome","family":"Bertherat","sequence":"additional","affiliation":[{"name":"Universit\u00e9 de Paris, Assistance Publique\u2013H\u00f4pitaux de Paris , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis V","family":"Syro","sequence":"additional","affiliation":[{"name":"Hospital Pablo Tobon Uribe and Clinica Medellin \u2013 Grupo Quir\u00f3nsalud , Medellin , Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9517-338X","authenticated-orcid":false,"given":"Gerald","family":"Raverot","sequence":"additional","affiliation":[{"name":"Hospices Civils de Lyon and Lyon 1 University , Lyon , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9817-9875","authenticated-orcid":false,"given":"Martin","family":"Reincke","sequence":"additional","affiliation":[{"name":"University Hospital of LMU, Ludwig-Maximilians-Universit\u00e4t , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3484-8440","authenticated-orcid":false,"given":"Gudmundur","family":"Johannsson","sequence":"additional","affiliation":[{"name":"Sahlgrenska University Hospital & Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Beckers","sequence":"additional","affiliation":[{"name":"University of Li\u00e8ge , Li\u00e8ge , Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fleseriu","sequence":"additional","affiliation":[{"name":"Oregon Health & Science University , Portland, OR , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6783-3398","authenticated-orcid":false,"given":"Andrea","family":"Giustina","sequence":"additional","affiliation":[{"name":"San Raffaele Vita-Salute University and IRCCS Hospital , Milan , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A H","family":"Wass","sequence":"additional","affiliation":[{"name":"University of Oxford , Oxford , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken K Y","family":"Ho","sequence":"additional","affiliation":[{"name":"The Garvan Institute of Medical Research and St. Vincents Hospital , Sydney , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,4,8]]},"reference":[{"issue":"10","key":"2022112513594875400_CIT0001","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1056\/NEJMra1810772","article-title":"Pituitary-tumor endocrinopathies","volume":"382","author":"Melmed","year":"2020","journal-title":"N Engl J Med."},{"issue":"5","key":"2022112513594875400_CIT0002","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1001\/jama.2016.19699","article-title":"Diagnosis and treatment of pituitary adenomas: a review","volume":"317","author":"Molitch","year":"2017","journal-title":"JAMA."},{"issue":"10","key":"2022112513594875400_CIT0003","doi-asserted-by":"crossref","first-page":"R375","DOI":"10.1530\/ERC-20-0136","article-title":"The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs)","volume":"27","author":"Yavropoulou","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"7","key":"2022112513594875400_CIT0004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s40618-017-0803-y","article-title":"Pituitary adenomas, stem cells, and cancer stem cells: what\u2019s new?","volume":"41","author":"Caffarini","year":"2018","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"2022112513594875400_CIT0005","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1210\/er.2009-0008","article-title":"Genetic regulation of pituitary gland development in human and mouse","volume":"30","author":"Kelberman","year":"2009","journal-title":"Endocr Rev."},{"issue":"7","key":"2022112513594875400_CIT0006","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1128\/MCB.01885-08","article-title":"Distinct developmental roles of cell cycle inhibitors p57Kip2 and p27Kip1 distinguish pituitary progenitor cell cycle exit from cell cycle reentry of differentiated cells","volume":"29","author":"Bilodeau","year":"2009","journal-title":"Mol Cell Biol."},{"issue":"3","key":"2022112513594875400_CIT0007","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1152\/physrev.00006.2006","article-title":"Molecular physiology of pituitary development: signaling and transcriptional networks","volume":"87","author":"Zhu","year":"2007","journal-title":"Physiol Rev."},{"key":"2022112513594875400_CIT0008","doi-asserted-by":"crossref","first-page":"604519","DOI":"10.3389\/fendo.2020.604519","article-title":"Pituitary remodeling throughout life: are resident stem cells involved?","volume":"11","author":"Laporte","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"4","key":"2022112513594875400_CIT0009","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1210\/er.2010-0011","article-title":"Pituitary stem cell update and potential implications for treating hypopituitarism","volume":"32","author":"Castinetti","year":"2011","journal-title":"Endocr Rev."},{"issue":"9","key":"2022112513594875400_CIT0010","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1210\/en.2005-0185","article-title":"The adult pituitary contains a cell population displaying stem\/progenitor cell and early embryonic characteristics","volume":"146","author":"Chen","year":"2005","journal-title":"Endocrinology."},{"issue":"12","key":"2022112513594875400_CIT0011","doi-asserted-by":"crossref","first-page":"3293","DOI":"10.1210\/me.2006-0293","article-title":"The notch signaling system is present in the postnatal pituitary: marked expression and regulatory activity in the newly discovered side population","volume":"20","author":"Chen","year":"2006","journal-title":"Mol Endocrinol."},{"issue":"9","key":"2022112513594875400_CIT0012","doi-asserted-by":"crossref","first-page":"4386","DOI":"10.1210\/en.2009-0206","article-title":"The notch target gene HES1 regulates cell cycle inhibitor expression in the developing pituitary","volume":"150","author":"Monahan","year":"2009","journal-title":"Endocrinology."},{"issue":"19","key":"2022112513594875400_CIT0013","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1101\/gad.1444706","article-title":"Sustained Notch signaling in progenitors is required for sequential emergence of distinct cell lineages during organogenesis","volume":"20","author":"Zhu","year":"2006","journal-title":"Genes Dev."},{"issue":"2","key":"2022112513594875400_CIT0014","doi-asserted-by":"crossref","first-page":"bqaa002","DOI":"10.1210\/endocr\/bqaa002","article-title":"PROP1-dependent retinoic acid signaling regulates developmental pituitary morphogenesis and hormone expression","volume":"161","author":"Cheung","year":"2020","journal-title":"Endocrinology."},{"issue":"1","key":"2022112513594875400_CIT0015","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1038\/s41467-019-11791-9","article-title":"Pioneer and nonpioneer factor cooperation drives lineage specific chromatin opening","volume":"10","author":"Mayran","year":"2019","journal-title":"Nat Commun."},{"issue":"17","key":"2022112513594875400_CIT0016","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1073\/pnas.0801644105","article-title":"Genetic approaches identify adult pituitary stem cells","volume":"105","author":"Gleiberman","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2022112513594875400_CIT0017","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1073\/pnas.0707886105","article-title":"SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland","volume":"105","author":"Fauquier","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"4","key":"2022112513594875400_CIT0018","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1177\/1947601910370979","article-title":"Postnatal Pax7 progenitor gives rise to pituitary adenomas","volume":"1","author":"Hosoyama","year":"2010","journal-title":"Genes Cancer."},{"issue":"11","key":"2022112513594875400_CIT0019","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1172\/JCI20401","article-title":"Mechanisms for pituitary tumorigenesis: the plastic pituitary","volume":"112","author":"Melmed","year":"2003","journal-title":"J Clin Invest."},{"issue":"3-4","key":"2022112513594875400_CIT0020","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1023\/A:1009966812195","article-title":"Cytology of pituitary thyrotroph hyperplasia in protracted primary hypothyroidism","volume":"1","author":"Alkhani","year":"1999","journal-title":"Pituitary."},{"issue":"7","key":"2022112513594875400_CIT0021","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/1043-2760(92)90127-M","article-title":"Pituitary lactotrophs: endocrine, paracrine, juxtacrine, and autocrine interactions","volume":"3","author":"Ben-Jonathan","year":"1992","journal-title":"Trends Endocrinol Metab."},{"issue":"11","key":"2022112513594875400_CIT0022","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1038\/15275","article-title":"Early involvement of estrogen-induced pituitary tumor transforming gene and fibroblast growth factor expression in prolactinoma pathogenesis","volume":"5","author":"Heaney","year":"1999","journal-title":"Nat Med."},{"issue":"1","key":"2022112513594875400_CIT0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1042-3680(02)00035-9","article-title":"Pathology of pituitary tumors","volume":"14","author":"Sanno","year":"2003","journal-title":"Neurosurg Clin N Am"},{"issue":"2","key":"2022112513594875400_CIT0024","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0025-7125(16)31800-4","article-title":"A functional anatomy of the endocrine hypothalamus and hypophysis","volume":"62","author":"Ezrin","year":"1978","journal-title":"Med Clin North Am."},{"issue":"4","key":"2022112513594875400_CIT0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S2213-8587(21)00002-4","article-title":"Endocrine disorders in Prader-Willi syndrome: a model to understand and treat hypothalamic dysfunction","volume":"9","author":"Tauber","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"6434","key":"2022112513594875400_CIT0026","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/364190a0","article-title":"Cell differentiation. The road not taken","volume":"364","author":"Montminy","year":"1993","journal-title":"Nature."},{"issue":"8","key":"2022112513594875400_CIT0027","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.1210\/jc.2007-0836","article-title":"Long-term management of prolactinomas","volume":"92","author":"Schlechte","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112513594875400_CIT0028","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112513594875400_CIT0029","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1111\/cen.13835","article-title":"Gender-affirming hormone therapy and the risk of sex hormone-dependent tumours in transgender individuals-a systematic review","volume":"89","author":"McFarlane","year":"2018","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"9","key":"2022112513594875400_CIT0030","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1210\/endo.139.9.6209","article-title":"Neuroendocrine and reproductive functions in male mice with targeted disruption of the prolactin gene","volume":"139","author":"Steger","year":"1998","journal-title":"Endocrinology."},{"issue":"23","key":"2022112513594875400_CIT0031","doi-asserted-by":"crossref","first-page":"6926","DOI":"10.1093\/emboj\/16.23.6926","article-title":"Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene","volume":"16","author":"Horseman","year":"1997","journal-title":"EMBO J."},{"key":"2022112513594875400_CIT0032","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3389\/fendo.2018.00768","article-title":"The mechanism and pathways of dopamine and dopamine agonists in prolactinomas","volume":"9","author":"Liu","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"23","key":"2022112513594875400_CIT0033","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa1805171","article-title":"Variant prolactin receptor in agalactia and hyperprolactinemia","volume":"379","author":"Kobayashi","year":"2018","journal-title":"N Engl J Med."},{"issue":"6","key":"2022112513594875400_CIT0034","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41574-019-0194-6","article-title":"Prolactin - a pleiotropic factor in health and disease","volume":"15","author":"Bernard","year":"2019","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/edrv-4-3-271","article-title":"Pathophysiology of acromegaly","volume":"4","author":"Melmed","year":"1983","journal-title":"Endocr Rev."},{"key":"2022112513594875400_CIT0036","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40842-018-0068-1","article-title":"Growth hormone: isoforms, clinical aspects and assays interference","volume":"4","author":"Ribeiro de Oliveira Longo Schweizer","year":"2018","journal-title":"Clin Diabetes Endocrinol."},{"issue":"6008","key":"2022112513594875400_CIT0037","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/314279a0","article-title":"Independent effects of growth hormone releasing factor on growth hormone release and gene transcription","volume":"314","author":"Barinaga","year":"1985","journal-title":"Nature."},{"key":"2022112513594875400_CIT0038","article-title":"Normal physiology of growth hormone in adults.","volume-title":"Endotext","author":"Olarescu","year":"2000"},{"issue":"2","key":"2022112513594875400_CIT0039","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1172\/JCI112832","article-title":"Insulinlike growth factor I regulation of growth hormone gene transcription in primary rat pituitary cells","volume":"79","author":"Yamashita","year":"1987","journal-title":"J Clin Invest."},{"key":"2022112513594875400_CIT0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.mce.2015.08.024","article-title":"Animal models of pituitary neoplasia","volume":"421","author":"Lines","year":"2016","journal-title":"Mol Cell Endocrinol."},{"issue":"5","key":"2022112513594875400_CIT0041","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1172\/JCI110708","article-title":"Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor","volume":"70","author":"Thorner","year":"1982","journal-title":"J Clin Invest."},{"issue":"6236","key":"2022112513594875400_CIT0042","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/340692a0","article-title":"GTPase inhibiting mutations activate the alpha chain of Gs and stimulate adenylyl cyclase in human pituitary tumours","volume":"340","author":"Landis","year":"1989","journal-title":"Nature."},{"issue":"25","key":"2022112513594875400_CIT0043","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1056\/NEJMoa1408028","article-title":"Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation","volume":"371","author":"Trivellin","year":"2014","journal-title":"N Engl J Med."},{"issue":"6762","key":"2022112513594875400_CIT0044","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature."},{"issue":"51","key":"2022112513594875400_CIT0045","doi-asserted-by":"crossref","first-page":"20452","DOI":"10.1073\/pnas.0811680106","article-title":"Growth hormone-releasing hormone as an agonist of the ghrelin receptor GHS-R1a","volume":"105","author":"Casanueva","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022112513594875400_CIT0046","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1210\/en.2002-220852","article-title":"Interrelationship between the novel peptide ghrelin and somatostatin\/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion","volume":"144","author":"Tannenbaum","year":"2003","journal-title":"Endocrinology."},{"issue":"4","key":"2022112513594875400_CIT0047","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0896-6273(03)00063-1","article-title":"The distribution and mechanism of action of ghrelin in the CNS demonstrates a novel hypothalamic circuit regulating energy homeostasis","volume":"37","author":"Cowley","year":"2003","journal-title":"Neuron."},{"issue":"4","key":"2022112513594875400_CIT0048","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1124\/pr.117.015388","article-title":"International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature","volume":"70","author":"Gunther","year":"2018","journal-title":"Pharmacol Rev."},{"issue":"4","key":"2022112513594875400_CIT0049","doi-asserted-by":"crossref","first-page":"T99","DOI":"10.1530\/JME-15-0289","article-title":"60 YEARS OF POMC: transcriptional and epigenetic regulation of POMC gene expression","volume":"56","author":"Drouin","year":"2016","journal-title":"J Mol Endocrinol."},{"issue":"9","key":"2022112513594875400_CIT0050","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1172\/JCI7924","article-title":"Inhibitory roles for SHP-1 and SOCS-3 following pituitary proopiomelanocortin induction by leukemia inhibitory factor","volume":"104","author":"Bousquet","year":"1999","journal-title":"J Clin Invest."},{"key":"2022112513594875400_CIT0051","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1749-6632.2008.03620.x","article-title":"Regulation of proopiomelanocortin gene expression: an overview of the signaling cascades, transcription factors, and responsive elements involved","volume":"1163","author":"Jenks","year":"2009","journal-title":"Ann N Y Acad Sci."},{"issue":"6","key":"2022112513594875400_CIT0052","doi-asserted-by":"crossref","first-page":"R233","DOI":"10.1530\/ERC-10-0334","article-title":"The role of somatostatin and dopamine D2 receptors in endocrine tumors","volume":"18","author":"Gatto","year":"2011","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2022112513594875400_CIT0053","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0054","doi-asserted-by":"crossref","first-page":"T77","DOI":"10.1530\/JME-15-0323","article-title":"60 YEARS OF POMC: biosynthesis, trafficking, and secretion of pro-opiomelanocortin-derived peptides","volume":"56","author":"Cawley","year":"2016","journal-title":"J Mol Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0055","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/JME-17-0308","article-title":"Molecular regulation of follicle-stimulating hormone synthesis, secretion and action","volume":"60","author":"Das","year":"2018","journal-title":"J Mol Endocrinol."},{"key":"2022112513594875400_CIT0056","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.mce.2017.10.015","article-title":"Gonadotropin regulation by pulsatile GnRH: signaling and gene expression","volume":"463","author":"Stamatiades","year":"2018","journal-title":"Mol Cell Endocrinol."},{"issue":"8","key":"2022112513594875400_CIT0057","first-page":"4486","article-title":"MKRN3 inhibits the reproductive axis through actions in kisspeptin-expressing neurons","volume":"130","author":"Abreu","year":"2020","journal-title":"J Clin Invest."},{"issue":"11","key":"2022112513594875400_CIT0058","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.1210\/en.2018-00653","article-title":"The gonadotropin-releasing hormone pulse generator","volume":"159","author":"Herbison","year":"2018","journal-title":"Endocrinology."},{"issue":"8","key":"2022112513594875400_CIT0059","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/s41574-020-0363-7","article-title":"Metabolic regulation of kisspeptin - the link between energy balance and reproduction","volume":"16","author":"Navarro","year":"2020","journal-title":"Nat Rev Endocrinol."},{"issue":"10","key":"2022112513594875400_CIT0060","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1172\/JCI64455","article-title":"Hyperprolactinemia and infertility: new insights","volume":"122","author":"Kaiser","year":"2012","journal-title":"J Clin Invest."},{"issue":"10","key":"2022112513594875400_CIT0061","doi-asserted-by":"crossref","first-page":"3791","DOI":"10.1172\/JCI63937","article-title":"Hyperprolactinemia-induced ovarian acyclicity is reversed by kisspeptin administration","volume":"122","author":"Sonigo","year":"2012","journal-title":"J Clin Invest."},{"key":"2022112513594875400_CIT0062","article-title":"Physiology of the hypothalamic-pituitary-thyroid axis.","volume-title":"Endotext","author":"Mariotti","year":"2000"},{"issue":"2-3","key":"2022112513594875400_CIT0063","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yfrne.2007.04.002","article-title":"Negative feedback regulation of hypophysiotropic thyrotropin-releasing hormone (TRH) synthesizing neurons: role of neuronal afferents and type 2 deiodinase","volume":"28","author":"Fekete","year":"2007","journal-title":"Front Neuroendocrinol."},{"key":"2022112513594875400_CIT0064","doi-asserted-by":"crossref","first-page":"100852","DOI":"10.1016\/j.yfrne.2020.100852","article-title":"The tumour microenvironment of pituitary neuroendocrine tumours","volume":"58","author":"Marques","year":"2020","journal-title":"Front Neuroendocrinol."},{"issue":"2","key":"2022112513594875400_CIT0065","doi-asserted-by":"crossref","first-page":"bnz003","DOI":"10.1210\/endrev\/bnz003","article-title":"Autoimmune pituitary disease: new concepts with clinical implications","volume":"41","author":"Yamamoto","year":"2020","journal-title":"Endocr Rev."},{"issue":"3","key":"2022112513594875400_CIT0066","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/BF00214569","article-title":"Immunocytochemical localization of S-100 protein in stellate cells (folliculo-stellate cells) of the anterior lobe of the normal human pituitary","volume":"241","author":"Girod","year":"1985","journal-title":"Cell Tissue Res."},{"issue":"2","key":"2022112513594875400_CIT0067","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/BF00430697","article-title":"Null cell adenoma of the human pituitary","volume":"387","author":"Kovacs","year":"1980","journal-title":"Virchows Arch A Pathol Anat Histol."},{"issue":"11","key":"2022112513594875400_CIT0068","doi-asserted-by":"crossref","first-page":"dgaa520","DOI":"10.1210\/clinem\/dgaa520","article-title":"Immune landscape of pituitary tumors reveals association between macrophages and gonadotroph tumor invasion","volume":"105","author":"Principe","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0069","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1006\/frne.1998.0176","article-title":"Pathophysiological role of the cytokine network in the anterior pituitary gland","volume":"20","author":"Arzt","year":"1999","journal-title":"Front Neuroendocrinol."},{"issue":"3","key":"2022112513594875400_CIT0070","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ecl.2020.05.001","article-title":"World Health Ozganization 2017 classification of pituitary tumors","volume":"49","author":"Lopes","year":"2020","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"3","key":"2022112513594875400_CIT0071","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12022-017-9498-z","article-title":"Overview of the 2017 WHO classification of pituitary tumors","volume":"28","author":"Mete","year":"2017","journal-title":"Endocr Pathol."},{"key":"2022112513594875400_CIT0072","article-title":"Introduction.","volume-title":"WHO Classification of Tumours of Endocrine Organs","author":"Osamura","year":"2017","edition":"4"},{"issue":"12","key":"2022112513594875400_CIT0073","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1038\/s41379-018-0110-y","article-title":"common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol."},{"key":"2022112513594875400_CIT0074","volume-title":"Tumours of the Sellar Region: Introduction. WHO Classification of Tumours of the Central Nervous System","author":"Lopes","year":"2022","edition":"5"},{"key":"2022112513594875400_CIT0075","volume-title":"Pituitary Gland: Introduction. WHO Classification of Tumours of Endocrine Organs","author":"Mete","year":"2022","edition":"5"},{"issue":"3","key":"2022112513594875400_CIT0076","doi-asserted-by":"crossref","first-page":"bvaa205","DOI":"10.1210\/jendso\/bvaa205","article-title":"Pituitary neoplasm nomenclature workshop: does adenoma stand the test of time?","volume":"5","author":"Ho","year":"2021","journal-title":"J Endocr Soc."},{"issue":"2","key":"2022112513594875400_CIT0077","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/(SICI)1097-0029(19971015)39:2<168::AID-JEMT8>3.0.CO;2-H","article-title":"Transcription factors in normal and neoplastic pituitary tissues","volume":"39","author":"Lloyd","year":"1997","journal-title":"Microsc Res Tech."},{"issue":"6","key":"2022112513594875400_CIT0078","first-page":"2165","article-title":"The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph","volume":"81","author":"Asa","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0079","first-page":"1281","article-title":"Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas","volume":"77","author":"Friend","year":"1993","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/eje.1.02326","article-title":"Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry","volume":"156","author":"Saeger","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0081","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s12022-015-9398-z","article-title":"The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas","volume":"26","author":"Nishioka","year":"2015","journal-title":"Endocr Pathol."},{"issue":"6","key":"2022112513594875400_CIT0082","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-20-1273","article-title":"Transcription factor immunohistochemistry in the diagnosis of pituitary tumours","volume":"184","author":"Lenders","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022112513594875400_CIT0083","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s11102-017-0855-1","article-title":"Histopathological classification of non-functioning pituitary neuroendocrine tumors","volume":"21","author":"Manojlovic-Gacic","year":"2018","journal-title":"Pituitary."},{"key":"2022112513594875400_CIT0084","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.humpath.2020.12.001","article-title":"Proposal of a clinically relevant working classification of pituitary neuroendocrine tumors based on pituitary transcription factors","volume":"110","author":"Silva-Ortega","year":"2021","journal-title":"Hum Pathol."},{"issue":"2","key":"2022112513594875400_CIT0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/BF03401473","article-title":"The gonadotroph origin of null cell adenomas","volume":"15","author":"Kontogeorgos","year":"2016","journal-title":"Hormones (Athens)."},{"issue":"6","key":"2022112513594875400_CIT0086","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2020.3.FOCUS20114","article-title":"Clinical characteristics and outcomes of null-cell versus silent gonadotroph adenomas in a series of 1166 pituitary adenomas from a single institution","volume":"48","author":"Haddad","year":"2020","journal-title":"Neurosurg Focus."},{"issue":"5","key":"2022112513594875400_CIT0087","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1007\/s11102-019-00981-9","article-title":"Clinical, pathologic, and imaging characteristics of pituitary null cell adenomas as defined according to the 2017 World Health Organization criteria: a case series from two pituitary centers","volume":"22","author":"Almeida","year":"2019","journal-title":"Pituitary."},{"issue":"5","key":"2022112513594875400_CIT0088","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1365-2265.2009.03583.x","article-title":"The natural history of surgically treated but radiotherapy-naive nonfunctioning pituitary adenomas","volume":"71","author":"O\u2019Sullivan","year":"2009","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022112513594875400_CIT0089","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0090","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ecl.2020.05.008","article-title":"Aggressive pituitary adenomas and carcinomas","volume":"49","author":"Ilie","year":"2020","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"2","key":"2022112513594875400_CIT0091","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1159\/000371806","article-title":"Aggressive pituitary tumors","volume":"101","author":"Chatzellis","year":"2015","journal-title":"Neuroendocrinology."},{"issue":"6","key":"2022112513594875400_CIT0092","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","article-title":"Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment","volume":"76","author":"Raverot","year":"2012","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2022112513594875400_CIT0093","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00701-019-03879-4","article-title":"Ki-67 labeling index and expression of p53 are non-predictive for invasiveness and tumor size in functional and nonfunctional pituitary adenomas","volume":"161","author":"Grimm","year":"2019","journal-title":"Acta Neurochir (Wien)."},{"key":"2022112513594875400_CIT0094","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jocn.2016.09.014","article-title":"Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas","volume":"34","author":"Zaidi","year":"2016","journal-title":"J Clin Neurosci."},{"issue":"3","key":"2022112513594875400_CIT0095","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1227\/01.NEU.0000349930.66434.82","article-title":"Ki-67 in pituitary neoplasms: a review--part I","volume":"65","author":"Salehi","year":"2009","journal-title":"Neurosurgery"},{"issue":"9","key":"2022112513594875400_CIT0096","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1210\/jc.2017-00773","article-title":"Risk of recurrence in pituitary neuroendocrine tumors: a prospective study using a five-tiered classification","volume":"102","author":"Raverot","year":"2017","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0097","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00401-013-1084-y","article-title":"A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up","volume":"126","author":"Trouillas","year":"2013","journal-title":"Acta Neuropathol."},{"key":"2022112513594875400_CIT0098","doi-asserted-by":"crossref","first-page":"290","DOI":"10.3389\/fendo.2019.00290","article-title":"The epigenomics of pituitary adenoma","volume":"10","author":"Hauser","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"1","key":"2022112513594875400_CIT0099","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2019.11.002","article-title":"Pangenomic classification of pituitary neuroendocrine tumors","volume":"37","author":"Neou","year":"2020","journal-title":"Cancer Cell."},{"issue":"4","key":"2022112513594875400_CIT0100","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1530\/EJE-12-0864","article-title":"Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas","volume":"168","author":"Larkin","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0101","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-10-0586","article-title":"Relationship between cytokeratin staining patterns and clinico-pathological features in somatotropinomae","volume":"163","author":"Bakhtiar","year":"2010","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0102","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.ijrobp.2014.07.013","article-title":"Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study","volume":"90","author":"Xu","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys."},{"issue":"5","key":"2022112513594875400_CIT0103","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1227\/NEU.0000000000000657","article-title":"Crooke\u2019s cell tumors of the pituitary","volume":"76","author":"Di Ieva","year":"2015","journal-title":"Neurosurgery."},{"issue":"4","key":"2022112513594875400_CIT0104","first-page":"1039","article-title":"Recurrence in silent corticotroph adenomas after primary treatment: a systematic review and meta-analysis","volume":"104","author":"Fountas","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022112513594875400_CIT0106","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/ng.2764","article-title":"The Cancer Genome Atlas Pan-Cancer analysis project","volume":"45","author":"The Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nat Genet."},{"issue":"3","key":"2022112513594875400_CIT0107","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"The Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell."},{"issue":"6","key":"2022112513594875400_CIT0108","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma","volume":"46","author":"Assie","year":"2014","journal-title":"Nat Genet."},{"key":"2022112513594875400_CIT0109","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.2147\/DMSO.S226056","article-title":"Identification of transcriptional metabolic dysregulation in subtypes of pituitary adenoma by integrated bioinformatics analysis","volume":"12","author":"Hu","year":"2019","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"1","key":"2022112513594875400_CIT0110","doi-asserted-by":"crossref","first-page":"132","DOI":"10.7150\/thno.47525","article-title":"Transcriptomic analysis identifies a tumor subtype mRNA classifier for invasive non-functioning pituitary neuroendocrine tumor diagnostics","volume":"11","author":"Bao","year":"2021","journal-title":"Theranostics."},{"issue":"2","key":"2022112513594875400_CIT0111","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1677\/ERC-10-0018","article-title":"Differential gene expression profiles of invasive and non-invasive non-functioning pituitary adenomas based on microarray analysis","volume":"17","author":"Galland","year":"2010","journal-title":"Endocr Relat Cancer."},{"key":"2022112513594875400_CIT0112","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fendo.2017.00055","article-title":"Transcriptome analysis showed a differential signature between invasive and non-invasive corticotrophinomas","volume":"8","author":"de Araujo","year":"2017","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"8","key":"2022112513594875400_CIT0113","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/neuonc\/noab044","article-title":"DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features","volume":"23","author":"Mosella","year":"2021","journal-title":"Neuro Oncol."},{"issue":"17","key":"2022112513594875400_CIT0114","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/1078-0432.CCR-17-2206","article-title":"The epigenomic landscape of pituitary adenomas reveals specific alterations and differentiates among acromegaly, Cushing\u2019s disease and endocrine-inactive subtypes","volume":"24","author":"Salomon","year":"2018","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2022112513594875400_CIT0115","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1210\/jc.2018-01856","article-title":"DNA methylation of tumor suppressor genes in pituitary neuroendocrine tumors","volume":"104","author":"Garcia-Martinez","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0116","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.18632\/aging.202376","article-title":"Functional characterization of DLK1\/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors","volume":"13","author":"Chen","year":"2020","journal-title":"Aging (Albany NY)."},{"issue":"6","key":"2022112513594875400_CIT0117","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3171\/jns.1986.65.6.0733","article-title":"Pathology of invasive pituitary tumors with special reference to functional classification","volume":"65","author":"Scheithauer","year":"1986","journal-title":"J Neurosurg."},{"issue":"3","key":"2022112513594875400_CIT0118","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3171\/jns.1986.64.3.0402","article-title":"The occurrence of dural invasion in pituitary adenomas","volume":"64","author":"Selman","year":"1986","journal-title":"J Neurosurg."},{"issue":"6","key":"2022112513594875400_CIT0119","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.jocn.2009.10.015","article-title":"Surgical anatomy of the dural walls of the cavernous sinus","volume":"17","author":"Campero","year":"2010","journal-title":"J Clin Neurosci."},{"issue":"3","key":"2022112513594875400_CIT0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/0268869031000153099","article-title":"The \u201ccapsule\u201d of pituitary macroadenomas represents normal pituitary gland: a histopathological study","volume":"17","author":"Chacko","year":"2003","journal-title":"Br J Neurosurg."},{"issue":"12","key":"2022112513594875400_CIT0121","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.3390\/cancers11121936","article-title":"Pituitary adenomas and invasiveness from anatomo-surgical, radiological, and histological perspectives: a systematic literature review","volume":"11","author":"Serioli","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"2","key":"2022112513594875400_CIT0122","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10143-011-0360-3","article-title":"Cavernous sinus medial wall: dural or fibrous layer? Systematic review of the literature","volume":"35","author":"Goncalves","year":"2012","journal-title":"Neurosurg Rev"},{"issue":"5","key":"2022112513594875400_CIT0123","first-page":"403","article-title":"Intracavernous invagination of pituitary macro-adenomas","volume":"57","author":"Roux","year":"1996","journal-title":"Ann Endocrinol (Paris)."},{"issue":"3","key":"2022112513594875400_CIT0124","first-page":"527","article-title":"Meningeal architecture of the cavernous sinus: clinical and surgical implications","volume":"39","author":"Kawase","year":"1996","journal-title":"Neurosurgery"},{"issue":"4","key":"2022112513594875400_CIT0125","first-page":"857","article-title":"Are nonfunctioning pituitary adenomas extending into the cavernous sinus aggressive and\/or invasive?","volume":"49","author":"Yokoyama","year":"2001","journal-title":"Neurosurgery"},{"issue":"1","key":"2022112513594875400_CIT0126","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000495184","article-title":"Giant prolactinomas","volume":"109","author":"Shimon","year":"2019","journal-title":"Neuroendocrinology."},{"issue":"7","key":"2022112513594875400_CIT0127","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrendo.2014.64","article-title":"Aggressive pituitary adenomas--diagnosis and emerging treatments","volume":"10","author":"Di Ieva","year":"2014","journal-title":"Nat Rev Endocrinol."},{"key":"2022112513594875400_CIT0128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/neurosurgery\/16.CN_suppl_1.185","article-title":"Transphenoidal microsurgery of the normal and pathological pituitary","volume":"16","author":"Hardy","year":"1969","journal-title":"Clin Neurosurg."},{"issue":"4","key":"2022112513594875400_CIT0129","first-page":"610","article-title":"Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings","volume":"33","author":"Knosp","year":"1993","journal-title":"Neurosurgery"},{"issue":"4","key":"2022112513594875400_CIT0130","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg."},{"issue":"23","key":"2022112513594875400_CIT0131","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","article-title":"Precision medicine--personalized, problematic, and promising","volume":"372","author":"Jameson","year":"2015","journal-title":"N Engl J Med."},{"issue":"2","key":"2022112513594875400_CIT0132","doi-asserted-by":"crossref","first-page":"336","DOI":"10.3171\/2010.8.JNS10290","article-title":"Atypical pituitary adenomas: incidence, clinical characteristics, and implications","volume":"114","author":"Zada","year":"2011","journal-title":"J Neurosurg."},{"issue":"2","key":"2022112513594875400_CIT0133","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3171\/jns.2002.96.2.0195","article-title":"The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery","volume":"96","author":"Meij","year":"2002","journal-title":"J Neurosurg."},{"issue":"3","key":"2022112513594875400_CIT0134","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ando.2015.04.003","article-title":"Post-surgical management of non-functioning pituitary adenoma","volume":"76","author":"Cortet-Rudelli","year":"2015","journal-title":"Ann Endocrinol (Paris)."},{"issue":"4","key":"2022112513594875400_CIT0135","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00401-017-1769-8","article-title":"The 2017 World Health Organization classification of tumors of the pituitary gland: a summary","volume":"134","author":"Lopes","year":"2017","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2022112513594875400_CIT0136","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3390\/cancers12020514","article-title":"How to classify the pituitary neuroendocrine tumors (PitNET)s in 2020","volume":"12","author":"Trouillas","year":"2020","journal-title":"Cancers (Basel)."},{"issue":"2","key":"2022112513594875400_CIT0137","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1530\/EJE-06-0646","article-title":"Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men","volume":"156","author":"Shimon","year":"2007","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022112513594875400_CIT0138","doi-asserted-by":"crossref","first-page":"25","DOI":"10.23736\/S0390-5616.16.03889-3","article-title":"Transcranial approach in giant pituitary adenomas: results and outcome in a modern series","volume":"64","author":"Graillon","year":"2020","journal-title":"J Neurosurg Sci."},{"issue":"2","key":"2022112513594875400_CIT0139","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-020-09556-7","article-title":"The epidemiology of aggressive pituitary tumors (and its challenges)","volume":"21","author":"Dekkers","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"2","key":"2022112513594875400_CIT0140","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11154-019-09531-x","article-title":"Definition and diagnosis of aggressive pituitary tumors","volume":"21","author":"Kasuki","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"2","key":"2022112513594875400_CIT0141","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer."},{"issue":"9","key":"2022112513594875400_CIT0142","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1210\/js.2019-00130","article-title":"Comparison of radiographic approaches to assess treatment response in pituitary adenomas: is RECIST or RANO good enough?","volume":"3","author":"Imber","year":"2019","journal-title":"J Endocr Soc."},{"issue":"11","key":"2022112513594875400_CIT0143","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/s41574-021-00550-w","article-title":"Aggressive pituitary tumours and pituitary carcinomas","volume":"17","author":"Raverot","year":"2021","journal-title":"Nat Rev Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0144","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1530\/EJE-17-0965","article-title":"Both invasiveness and proliferation criteria predict recurrence of non-functioning pituitary macroadenomas after surgery: a retrospective analysis of a monocentric cohort of 120 patients","volume":"178","author":"Lelotte","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2022112513594875400_CIT0145","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1530\/EJE-18-0749","article-title":"Validation of a clinicopathological score for the prediction of post-surgical evolution of pituitary adenoma: retrospective analysis on 566 patients from a tertiary care centre","volume":"180","author":"Asioli","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022112513594875400_CIT0146","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/cen.14197","article-title":"A practical algorithm to predict postsurgical recurrence and progression of pituitary neuroendocrine tumours (PitNET)s","volume":"93","author":"Guaraldi","year":"2020","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"2022112513594875400_CIT0147","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1210\/mend.11.4.9911","article-title":"Isolation and characterization of a pituitary tumor-transforming gene (PTTG)","volume":"11","author":"Pei","year":"1997","journal-title":"Mol Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0148","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1210\/jc.2009-1191","article-title":"Prognostic factors in prolactin pituitary tumors: clinical, histological, and molecular data from a series of 94 patients with a long postoperative follow-up","volume":"95","author":"Raverot","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0149","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s11102-012-0454-0","article-title":"Prevalence and incidence of pituitary adenomas: a population based study in Malta","volume":"16","author":"Gruppetta","year":"2013","journal-title":"Pituitary."},{"issue":"6","key":"2022112513594875400_CIT0150","first-page":"7121","article-title":"Function of cell-cycle regulators in predicting silent pituitary adenoma progression following surgical resection","volume":"14","author":"Park","year":"2017","journal-title":"Oncol Lett."},{"issue":"45","key":"2022112513594875400_CIT0151","doi-asserted-by":"crossref","first-page":"17498","DOI":"10.1073\/pnas.0804810105","article-title":"p21(Cip1) restrains pituitary tumor growth","volume":"105","author":"Chesnokova","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"issue":"8","key":"2022112513594875400_CIT0152","first-page":"1613","article-title":"Frequent loss of heterozygosity at the retinoblastoma susceptibility gene (RB) locus in aggressive pituitary tumors: evidence for a chromosome 13 tumor suppressor gene other than RB","volume":"55","author":"Pei","year":"1995","journal-title":"Cancer Res."},{"issue":"1","key":"2022112513594875400_CIT0153","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1186\/s40478-020-01067-5","article-title":"Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis","volume":"8","author":"Lasolle","year":"2020","journal-title":"Acta Neuropathol Commun."},{"issue":"7","key":"2022112513594875400_CIT0154","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1158\/1078-0432.CCR-16-0790","article-title":"Landscape of genomic alterations in pituitary adenomas","volume":"23","author":"Bi","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2022112513594875400_CIT0155","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1210\/clinem\/dgaa853","article-title":"USP8 and TP53 drivers are associated with CNV in a corticotroph adenoma cohort enriched for aggressive tumors","volume":"106","author":"Uzilov","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112513594875400_CIT0156","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1172\/JCI138540","article-title":"DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas","volume":"130","author":"Ben-Shlomo","year":"2020","journal-title":"J Clin Invest."},{"issue":"8","key":"2022112513594875400_CIT0157","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1210\/jcem.85.8.6754","article-title":"Role of matrix metalloproteinase 9 in pituitary tumor behavior","volume":"85","author":"Turner","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022112513594875400_CIT0158","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cancers11101605","article-title":"The microenvironment of pituitary tumors-biological and therapeutic implications","volume":"11","author":"Ilie","year":"2019","journal-title":"Cancers (Basel)."},{"issue":"11","key":"2022112513594875400_CIT0159","first-page":"1708","article-title":"Pituitary-directed leukemia inhibitory factor transgene causes Cushing\u2019s syndrome: neuro-immune-endocrine modulation of pituitary development","volume":"12","author":"Yano","year":"1998","journal-title":"Mol Endocrinol."},{"issue":"12","key":"2022112513594875400_CIT0160","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1172\/JCI200114662","article-title":"The central role of SOCS-3 in integrating the neuro-immunoendocrine interface","volume":"108","author":"Auernhammer","year":"2001","journal-title":"J Clin Invest."},{"issue":"5","key":"2022112513594875400_CIT0161","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1007\/s11102-021-01178-9","article-title":"Pituitary metastases from neuroendocrine neoplasms: case report and narrative review","volume":"24","author":"Ragni","year":"2021","journal-title":"Pituitary."},{"issue":"2","key":"2022112513594875400_CIT0162","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12022-019-9568-5","article-title":"An institutional experience of tumor progression to pituitary carcinoma in a 15-year cohort of 1055 consecutive pituitary neuroendocrine tumors","volume":"30","author":"Alshaikh","year":"2019","journal-title":"Endocr Pathol."},{"issue":"2","key":"2022112513594875400_CIT0163","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11154-020-09551-y","article-title":"Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives","volume":"21","author":"Burman","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"key":"2022112513594875400_CIT0164","doi-asserted-by":"crossref","first-page":"700007","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: a systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol."},{"key":"2022112513594875400_CIT0165","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3389\/fendo.2018.00318","article-title":"Temozolomide and pituitary tumors: current understanding, unresolved issues, and future directions","volume":"9","author":"Syro","year":"2018","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"5","key":"2022112513594875400_CIT0166","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Clinical review: diagnosis and management of pituitary carcinomas","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022112513594875400_CIT0167","doi-asserted-by":"crossref","first-page":"3649","DOI":"10.1210\/jc.2011-2031","article-title":"Clinical review: pituitary carcinoma: difficult diagnosis and treatment","volume":"96","author":"Heaney","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0168","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1007\/s11102-018-0872-8","article-title":"Corticotrophic pituitary carcinoma with cervical metastases: case series and literature review","volume":"21","author":"Yoo","year":"2018","journal-title":"Pituitary."},{"issue":"3","key":"2022112513594875400_CIT0169","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"47","key":"2022112513594875400_CIT0170","doi-asserted-by":"crossref","first-page":"e5268","DOI":"10.1097\/MD.0000000000005268","article-title":"Genetic aspects of pituitary carcinoma: a systematic review","volume":"95","author":"Yang","year":"2016","journal-title":"Medicine (Baltim)."},{"issue":"4","key":"2022112513594875400_CIT0171","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1210\/clinem\/dgaa749","article-title":"Corticotroph aggressive pituitary tumors and carcinomas frequently harbor ATRX mutations","volume":"106","author":"Casar-Borota","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112513594875400_CIT0172","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.3390\/cancers13061395","article-title":"Large scale molecular studies of pituitary neuroendocrine tumors: novel markers, mechanisms and translational perspectives","volume":"13","author":"Peculis","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"6","key":"2022112513594875400_CIT0173","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1210\/endrev\/bnaa006","article-title":"Novel insights into pituitary tumorigenesis: genetic and epigenetic mechanisms","volume":"41","author":"Srirangam Nadhamuni","year":"2020","journal-title":"Endocr Rev."},{"key":"2022112513594875400_CIT0174","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3389\/fendo.2020.00313","article-title":"Pituispheres contain genetic variants characteristic to pituitary adenoma tumor tissue","volume":"11","author":"Peculis","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"6","key":"2022112513594875400_CIT0175","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1210\/jcem-71-6-1427","article-title":"Clonal origin of pituitary adenomas","volume":"71","author":"Herman","year":"1990","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0176","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3171\/jns.1990.73.5.0731","article-title":"Clonal origin of pituitary adenomas","volume":"73","author":"Jacoby","year":"1990","journal-title":"J Neurosurg."},{"issue":"3","key":"2022112513594875400_CIT0177","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4103\/neuroindia.NI_330_17","article-title":"Genetics of pituitary adenomas","volume":"65","author":"Shaid","year":"2017","journal-title":"Neurol India."},{"issue":"7","key":"2022112513594875400_CIT0178","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ng.3322","article-title":"Common variants at 10p12.31, 10q21.1 and 13q12.13 are associated with sporadic pituitary adenoma","volume":"47","author":"Ye","year":"2015","journal-title":"Nat Genet."},{"issue":"1","key":"2022112513594875400_CIT0179","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/ng.3166","article-title":"Mutations in the deubiquitinase gene USP8 cause Cushing\u2019s disease","volume":"47","author":"Reincke","year":"2015","journal-title":"Nat Genet."},{"issue":"11","key":"2022112513594875400_CIT0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/cr.2016.114","article-title":"The genome-wide mutational landscape of pituitary adenomas","volume":"26","author":"Song","year":"2016","journal-title":"Cell Res."},{"issue":"12","key":"2022112513594875400_CIT0181","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/1541-7786.MCR-19-0434","article-title":"Genetic and epigenetic characterization of growth hormone-secreting pituitary tumors","volume":"17","author":"Valimaki","year":"2019","journal-title":"Mol Cancer Res."},{"issue":"7","key":"2022112513594875400_CIT0182","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/onc.2013.16","article-title":"PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility","volume":"33","author":"Zhou","year":"2014","journal-title":"Oncogene."},{"issue":"8","key":"2022112513594875400_CIT0183","doi-asserted-by":"crossref","first-page":"e2887","DOI":"10.1210\/clinem\/dgab257","article-title":"Soluble alpha klotho in acromegaly: comparison with traditional markers of disease activity","volume":"106","author":"Schweizer","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0184","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1172\/JCI78173","article-title":"STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hypersecretion","volume":"125","author":"Zhou","year":"2015","journal-title":"J Clin Invest."},{"issue":"4","key":"2022112513594875400_CIT0185","first-page":"842","article-title":"H-ras mutations in human pituitary carcinoma metastases","volume":"78","author":"Pei","year":"1994","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0186","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s11102-021-01151-6","article-title":"Identification of mutant K-RAS in pituitary macroadenoma","volume":"24","author":"Aran","year":"2021","journal-title":"Pituitary."},{"issue":"6","key":"2022112513594875400_CIT0187","doi-asserted-by":"crossref","first-page":"R235","DOI":"10.1530\/EJE-19-0602","article-title":"Somatic and germline mutations in the pathogenesis of pituitary adenomas","volume":"181","author":"Vandeva","year":"2019","journal-title":"Eur J Endocrinol."},{"issue":"10","key":"2022112513594875400_CIT0188","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1210\/jc.2015-3129","article-title":"Whole-genome sequencing of growth hormone (GH)-secreting pituitary adenomas","volume":"100","author":"Valimaki","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0189","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-15-1064","article-title":"Landscape of somatic mutations in sporadic GH-secreting pituitary adenomas","volume":"174","author":"Ronchi","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0190","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing\u2019s disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res."},{"issue":"16","key":"2022112513594875400_CIT0191","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3390\/cancers13164022","article-title":"Genetic profiling of a cohort of Italian patients with ACTH-secreting pituitary tumors and characterization of a Novel USP8 gene variant","volume":"13","author":"Treppiedi","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"4","key":"2022112513594875400_CIT0192","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s11102-019-00973-9","article-title":"Cushing\u2019s disease due to somatic USP8 mutations: a systematic review and meta-analysis","volume":"22","author":"Wanichi","year":"2019","journal-title":"Pituitary."},{"issue":"10","key":"2022112513594875400_CIT0193","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/neuonc\/noz109","article-title":"Driver mutations in USP8 wild-type Cushing\u2019s disease","volume":"21","author":"Sbiera","year":"2019","journal-title":"Neuro Oncol."},{"issue":"1","key":"2022112513594875400_CIT0194","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1038\/s41467-018-05275-5","article-title":"Identification of recurrent USP48 and BRAF mutations in Cushing\u2019s disease","volume":"9","author":"Chen","year":"2018","journal-title":"Nat Commun."},{"issue":"12","key":"2022112513594875400_CIT0195","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1172\/JCI60417","article-title":"EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas","volume":"121","author":"Fukuoka","year":"2011","journal-title":"J Clin Invest."},{"issue":"1","key":"2022112513594875400_CIT0196","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1677\/ERC-08-0167","article-title":"Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors","volume":"16","author":"Lin","year":"2009","journal-title":"Endocr Relat Cancer."},{"issue":"9","key":"2022112513594875400_CIT0197","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1590\/S0100-879X2012007500115","article-title":"Mutation and genomic amplification of the PIK3CA proto-oncogene in pituitary adenomas","volume":"45","author":"Murat","year":"2012","journal-title":"Braz J Med Biol Res."},{"issue":"1","key":"2022112513594875400_CIT0198","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000514862","article-title":"Pituitary tumors: genetic and molecular factors underlying pathogenesis and clinical behavior","volume":"112","author":"Spada","year":"2022","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2022112513594875400_CIT0199","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1038\/s41467-020-16052-8","article-title":"Somatic SF3B1 hotspot mutation in prolactinomas","volume":"11","author":"Li","year":"2020","journal-title":"Nat Commun."},{"issue":"1","key":"2022112513594875400_CIT0200","first-page":"124","article-title":"Nelson\u2019s syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene","volume":"81","author":"Karl","year":"1996","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0201","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1046\/j.1365-2265.2002.01639.x","article-title":"Glucocorticoid receptor gene polymorphisms in ACTH-secreting pituitary tumours","volume":"57","author":"Antonini","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"2022112513594875400_CIT0202","doi-asserted-by":"crossref","first-page":"bqab167","DOI":"10.1210\/endocr\/bqab167","article-title":"Effect of 3 NR3C1 mutations in the pathogenesis of pituitary ACTH adenoma","volume":"162","author":"Miao","year":"2021","journal-title":"Endocrinology."},{"issue":"7","key":"2022112513594875400_CIT0203","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1111\/j.1365-2826.2011.02155.x","article-title":"The glucose-dependent insulinotropic polypeptide receptor is overexpressed amongst GNAS1 mutation-negative somatotropinomas and drives growth hormone (GH)-promoter activity in GH3 cells","volume":"23","author":"Occhi","year":"2011","journal-title":"J Neuroendocrinol."},{"issue":"5","key":"2022112513594875400_CIT0204","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1210\/jc.2018-01504","article-title":"Hypermethylator phenotype and ectopic GIP receptor in GNAS mutation-negative somatotropinomas","volume":"104","author":"Hage","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0205","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1530\/EJE-16-0831","article-title":"The GIP\/GIPR axis is functionally linked to GH-secretion increase in a significant proportion of gsp(-) somatotropinomas","volume":"176","author":"Regazzo","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"14","key":"2022112513594875400_CIT0206","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1056\/NEJM199210013271402","article-title":"Gastric inhibitory polypeptide-dependent cortisol hypersecretion--a new cause of Cushing\u2019s syndrome","volume":"327","author":"Lacroix","year":"1992","journal-title":"N Engl J Med."},{"issue":"6","key":"2022112513594875400_CIT0207","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1172\/JCI116524","article-title":"Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations","volume":"91","author":"Thakker","year":"1993","journal-title":"J Clin Invest."},{"issue":"3","key":"2022112513594875400_CIT0208","first-page":"818","article-title":"Allelic deletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker","volume":"82","author":"Bates","year":"1997","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0209","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1210\/er.2006-0042","article-title":"Pituitary tumor-transforming gene: physiology and implications for tumorigenesis","volume":"28","author":"Vlotides","year":"2007","journal-title":"Endocr Rev."},{"issue":"1","key":"2022112513594875400_CIT0210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/gcc.20162","article-title":"Common genetic changes in hereditary and sporadic pituitary adenomas detected by comparative genomic hybridization","volume":"43","author":"Pack","year":"2005","journal-title":"Genes Chromosomes Cancer."},{"issue":"6","key":"2022112513594875400_CIT0211","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1127>3.0.CO;2-E","article-title":"Chromosomal aberrations in sporadic pituitary tumors","volume":"91","author":"Trautmann","year":"2001","journal-title":"Int J Cancer."},{"issue":"5","key":"2022112513594875400_CIT0212","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2017-02287","article-title":"Genomic alterations and complex subclonal architecture in sporadic GH-secreting pituitary adenomas","volume":"103","author":"Hage","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0213","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-17-0702","article-title":"Gene expression profiling of fast- and slow-growing non-functioning gonadotroph pituitary adenomas","volume":"178","author":"Falch","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0214","doi-asserted-by":"crossref","first-page":"E796","DOI":"10.1210\/jc.2012-4028","article-title":"Whole-exome sequencing studies of nonfunctioning pituitary adenomas","volume":"98","author":"Newey","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112513594875400_CIT0215","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1172\/JCI142237","article-title":"Oncogene-induced DNA damage: cyclic AMP steps into the ring","volume":"130","author":"Fagin","year":"2020","journal-title":"J Clin Invest."},{"issue":"5","key":"2022112513594875400_CIT0216","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrendo.2011.40","article-title":"Pathogenesis of pituitary tumors","volume":"7","author":"Melmed","year":"2011","journal-title":"Nat Rev Endocrinol."},{"issue":"21","key":"2022112513594875400_CIT0217","doi-asserted-by":"crossref","first-page":"10564","DOI":"10.1158\/0008-5472.CAN-07-0974","article-title":"Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth","volume":"67","author":"Chesnokova","year":"2007","journal-title":"Cancer Res."},{"issue":"35","key":"2022112513594875400_CIT0218","doi-asserted-by":"crossref","first-page":"E3331","DOI":"10.1073\/pnas.1310589110","article-title":"Growth hormone is a cellular senescence target in pituitary and nonpituitary cells","volume":"110","author":"Chesnokova","year":"2013","journal-title":"Proc Natl Acad Sci USA."},{"issue":"3","key":"2022112513594875400_CIT0219","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.18632\/oncotarget.13577","article-title":"Autocrine IL-6 mediates pituitary tumor senescence","volume":"8","author":"Sapochnik","year":"2017","journal-title":"Oncotarget."},{"issue":"4","key":"2022112513594875400_CIT0220","doi-asserted-by":"crossref","first-page":"R241","DOI":"10.1530\/JME-17-0026","article-title":"Programmed cell senescence: role of IL-6 in the pituitary","volume":"58","author":"Sapochnik","year":"2017","journal-title":"J Mol Endocrinol."},{"issue":"6","key":"2022112513594875400_CIT0221","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s11102-019-00988-2","article-title":"A tale of pituitary adenomas: to NET or not to NET: Pituitary Society position statement","volume":"22","author":"Ho","year":"2019","journal-title":"Pituitary."},{"issue":"2","key":"2022112513594875400_CIT0222","first-page":"205","article-title":"Subclinical adenoma of the pituitary gland","volume":"12","author":"Costello","year":"1936","journal-title":"Am J Pathol"},{"issue":"5","key":"2022112513594875400_CIT0223","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1530\/EJE-15-0189","article-title":"The epidemiology of pituitary adenomas in Iceland, 1955-2012: a nationwide population-based study","volume":"173","author":"Agustsson","year":"2015","journal-title":"Eur J Endocrinol."},{"key":"2022112513594875400_CIT0224","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/B978-0-444-59602-4.00012-5","article-title":"Nonfunctioning pituitary tumors","volume":"124","author":"Molitch","year":"2014","journal-title":"Handb Clin Neurol."},{"issue":"1","key":"2022112513594875400_CIT0225","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1148\/radiology.144.1.7089241","article-title":"Regions of low density in the contrast-enhanced pituitary gland: normal and pathologic processes","volume":"144","author":"Chambers","year":"1982","journal-title":"Radiology."},{"issue":"2","key":"2022112513594875400_CIT0226","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2214\/ajr.143.2.377","article-title":"Size, shape, and appearance of the normal female pituitary gland","volume":"143","author":"Wolpert","year":"1984","journal-title":"AJR Am J Roentgenol."},{"issue":"2","key":"2022112513594875400_CIT0227","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/BF00327890","article-title":"CT of the normal pituitary gland","volume":"28","author":"Peyster","year":"1986","journal-title":"Neuroradiology."},{"issue":"10","key":"2022112513594875400_CIT0228","doi-asserted-by":"crossref","first-page":"817","DOI":"10.7326\/0003-4819-120-10-199405150-00001","article-title":"Pituitary magnetic resonance imaging in normal human volunteers: occult adenomas in the general population","volume":"120","author":"Hall","year":"1994","journal-title":"Ann Intern Med."},{"issue":"4","key":"2022112513594875400_CIT0229","first-page":"675","article-title":"Pituitary gland MR: a comparative study of healthy volunteers and patients with microadenomas","volume":"15","author":"Chong","year":"1994","journal-title":"AJNR Am J Neuroradiol."},{"issue":"12","key":"2022112513594875400_CIT0230","doi-asserted-by":"crossref","first-page":"4769","DOI":"10.1210\/jc.2006-1668","article-title":"High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"223","key":"2022112513594875400_CIT0231","first-page":"2172","article-title":"Epidemiology of pituitary adenoma: results of the first Swiss study","volume":"5","author":"Fontana","year":"2009","journal-title":"Rev Med Suisse."},{"issue":"3","key":"2022112513594875400_CIT0232","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","article-title":"Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK)","volume":"72","author":"Fernandez","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"9","key":"2022112513594875400_CIT0233","doi-asserted-by":"crossref","first-page":"4268","DOI":"10.1210\/jc.2010-0537","article-title":"Incidence of pituitary adenomas in Northern Finland in 1992-2007","volume":"95","author":"Raappana","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0234","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1530\/EJE-14-0144","article-title":"The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011","volume":"171","author":"Tjornstrand","year":"2014","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0235","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1007\/s11102-019-01027-w","article-title":"The tale in evolution: clarity, consistency and consultation, not contradiction and confusion","volume":"23","author":"Ho","year":"2020","journal-title":"Pituitary."},{"issue":"4","key":"2022112513594875400_CIT0236","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<804::AID-CNCR18>3.0.CO;2-3","article-title":"Pituitary carcinoma: a clinicopathologic study of 15 cases","volume":"79","author":"Pernicone","year":"1997","journal-title":"Cancer."},{"issue":"2","key":"2022112513594875400_CIT0237","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1530\/EJE-12-0084","article-title":"Predictors of morbidity and mortality in acromegaly: an Italian survey","volume":"167","author":"Arosio","year":"2012","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022112513594875400_CIT0238","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/EJE-16-1064","article-title":"Changes in the management and comorbidities of acromegaly over three decades: the French Acromegaly Registry","volume":"176","author":"Maione","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"12","key":"2022112513594875400_CIT0239","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1210\/jc.2014-2670","article-title":"Successful mortality reduction and control of comorbidities in patients with acromegaly followed at a highly specialized multidisciplinary clinic","volume":"99","author":"Mercado","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0240","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1530\/EJE-19-1023","article-title":"Management of Endocrine Disease: does gender matter in the management of acromegaly?","volume":"182","author":"Lenders","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0241","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1210\/jc.2010-1942","article-title":"Mortality and morbidity in Cushing\u2019s disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature","volume":"96","author":"Clayton","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0242","doi-asserted-by":"crossref","first-page":"R143","DOI":"10.1530\/EJE-14-0556","article-title":"Management of endocrine disease: mortality remains increased in Cushing\u2019s disease despite biochemical remission: a systematic review and meta-analysis","volume":"172","author":"van Haalen","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0243","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.ejim.2011.10.013","article-title":"Mortality in Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"23","author":"Graversen","year":"2012","journal-title":"Eur J Intern Med."},{"issue":"6","key":"2022112513594875400_CIT0244","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1210\/jc.2018-02524","article-title":"Overall and disease-specific mortality in patients with Cushing disease: a Swedish nationwide study","volume":"104","author":"Ragnarsson","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0245","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1742-1241.2010.02537.x","article-title":"Pituitary incidentalomas: a single-centre experience","volume":"65","author":"Anagnostis","year":"2011","journal-title":"Int J Clin Pract."},{"issue":"2","key":"2022112513594875400_CIT0246","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s12020-018-1570-z","article-title":"Complete evaluation of pituitary tumours in a single tertiary care institution","volume":"60","author":"Askitis","year":"2018","journal-title":"Endocrine."},{"issue":"3","key":"2022112513594875400_CIT0247","doi-asserted-by":"crossref","first-page":"527","DOI":"10.3171\/2014.5.JNS131819","article-title":"Descriptive epidemiology of pituitary tumors in the United States, 2004-2009","volume":"121","author":"Gittleman","year":"2014","journal-title":"J Neurosurg."},{"issue":"3","key":"2022112513594875400_CIT0248","doi-asserted-by":"crossref","first-page":"688","DOI":"10.3803\/EnM.2021.1000","article-title":"Descriptive epidemiology and survival analysis of prolactinomas and Cushing\u2019s disease in Korea","volume":"36","author":"Park","year":"2021","journal-title":"Endocrinol Metab (Seoul)."},{"issue":"1","key":"2022112513594875400_CIT0249","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly","volume":"2","author":"Holdaway","year":"1999","journal-title":"Pituitary."},{"issue":"3","key":"2022112513594875400_CIT0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1530\/EJE-16-0117","article-title":"Acromegaly incidence, prevalence, complications and long-term prognosis: a nationwide cohort study","volume":"175","author":"Dal","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0251","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11102-015-0701-2","article-title":"Incidence and prevalence of acromegaly in a large US health plan database","volume":"19","author":"Burton","year":"2016","journal-title":"Pituitary."},{"issue":"2","key":"2022112513594875400_CIT0252","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s11102-019-00951-1","article-title":"The incidence of Cushing\u2019s disease: a nationwide Swedish study","volume":"22","author":"Ragnarsson","year":"2019","journal-title":"Pituitary."},{"issue":"4","key":"2022112513594875400_CIT0253","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1365-2265.2011.04124.x","article-title":"Mortality and morbidity in Cushing\u2019s syndrome in New Zealand","volume":"75","author":"Bolland","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022112513594875400_CIT0254","first-page":"117","article-title":"Incidence and late prognosis of cushing\u2019s syndrome: a population-based study","volume":"86","author":"Lindholm","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0255","first-page":"1420","article-title":"Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality","volume":"85","author":"Nilsson","year":"2000","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0256","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1210\/jc.2014-3525","article-title":"Excess mortality and morbidity in patients with craniopharyngioma, especially in patients with childhood onset: a population-based study in Sweden","volume":"100","author":"Olsson","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0257","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s12020-019-02123-4","article-title":"Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients","volume":"67","author":"Ioachimescu","year":"2020","journal-title":"Endocrine."},{"issue":"4","key":"2022112513594875400_CIT0258","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11102-019-00960-0","article-title":"Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management","volume":"22","author":"Esposito","year":"2019","journal-title":"Pituitary."},{"issue":"4","key":"2022112513594875400_CIT0259","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1210\/jc.2010-1054","article-title":"Natural history of nonfunctioning pituitary adenomas and incidentalomas: a systematic review and metaanalysis","volume":"96","author":"Fernandez-Balsells","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"8","key":"2022112513594875400_CIT0260","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1055\/a-1143-5930","article-title":"Clinical and molecular update on genetic causes of pituitary adenomas","volume":"52","author":"Vasilev","year":"2020","journal-title":"Horm Metab Res."},{"issue":"5311","key":"2022112513594875400_CIT0261","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science."},{"issue":"9","key":"2022112513594875400_CIT0262","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1210\/jc.2012-1230","article-title":"Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1)","volume":"97","author":"Thakker","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0263","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1210\/jcem.87.2.8145","article-title":"Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study","volume":"87","author":"Verges","year":"2002","journal-title":"J Clin Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0264","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1210\/jc.2014-3659","article-title":"MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d\u2019etude des Tumeurs Endocrines","volume":"100","author":"Goudet","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112513594875400_CIT0265","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1046\/j.1365-2796.2003.01164.x","article-title":"The treatment of sporadic versus MEN1-related pituitary adenomas","volume":"253","author":"Beckers","year":"2003","journal-title":"J Intern Med."},{"issue":"4","key":"2022112513594875400_CIT0266","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/PAS.0b013e31815ade45","article-title":"Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients","volume":"32","author":"Trouillas","year":"2008","journal-title":"Am J Surg Pathol."},{"issue":"4","key":"2022112513594875400_CIT0267","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-12-0763","article-title":"Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don\u2019t forget MEN1 genetic analysis","volume":"168","author":"Cuny","year":"2013","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2022112513594875400_CIT0268","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1530\/ERC-15-0320","article-title":"Clinical and genetic characterization of pituitary gigantism: an international collaborative study in 208 patients","volume":"22","author":"Rostomyan","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"42","key":"2022112513594875400_CIT0269","doi-asserted-by":"crossref","first-page":"15558","DOI":"10.1073\/pnas.0603877103","article-title":"Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans","volume":"103","author":"Pellegata","year":"2006","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022112513594875400_CIT0270","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/B978-0-12-801238-3.66169-X","article-title":"Pituitary tumors associated with multiple endocrine neoplasia syndromes","author":"Rostomyan","year":"2019","journal-title":"Encyclopedia of Endocrine Diseases."},{"issue":"6","key":"2022112513594875400_CIT0271","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1210\/clinem\/dgaa160","article-title":"Germline CDKN1B loss-of-function variants cause pediatric Cushing\u2019s disease with or without an MEN4 phenotype","volume":"105","author":"Chasseloup","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0272","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/79238","article-title":"Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex","volume":"26","author":"Kirschner","year":"2000","journal-title":"Nat Genet."},{"key":"2022112513594875400_CIT0273","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/a-0753-4943","article-title":"Carney complex","volume":"127","author":"Kamilaris","year":"2019","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"2","key":"2022112513594875400_CIT0274","doi-asserted-by":"crossref","first-page":"K7","DOI":"10.1530\/EJE-17-0227","article-title":"PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex","volume":"177","author":"Kiefer","year":"2017","journal-title":"Eur J Endocrinol."},{"key":"2022112513594875400_CIT0275","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000345669","article-title":"Carney complex","volume":"41","author":"Espiard","year":"2013","journal-title":"Front Horm Res."},{"issue":"3","key":"2022112513594875400_CIT0276","doi-asserted-by":"crossref","first-page":"e436","DOI":"10.1210\/clinem\/dgaa002","article-title":"Frequency and incidence of Carney complex manifestations: a prospective multicenter study with a three-year follow-up","volume":"105","author":"Espiard","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112513594875400_CIT0277","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/01913120290104656","article-title":"Pituitary adenoma in Carney complex: an immunohistochemical, ultrastructural, and immunoelectron microscopic study","volume":"26","author":"Kurtkaya-Yapicier","year":"2002","journal-title":"Ultrastruct Pathol."},{"issue":"4","key":"2022112513594875400_CIT0278","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1046\/j.1365-2265.2002.01643.x","article-title":"Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours","volume":"57","author":"Kaltsas","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"17","key":"2022112513594875400_CIT0279","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJM193704292161701","article-title":"Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females","volume":"216","author":"Albright","year":"1937","journal-title":"N Engl J Med."},{"issue":"4","key":"2022112513594875400_CIT0280","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/archpedi.1937.01980040110009","article-title":"Osteodystrophia fibrosa","volume":"54","author":"McCune","year":"1937","journal-title":"Am J Dis Child"},{"issue":"Suppl 1","key":"2022112513594875400_CIT0281","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1750-1172-7-S1-S4","article-title":"McCune-Albright syndrome and the extraskeletal manifestations of fibrous dysplasia","volume":"7","author":"Collins","year":"2012","journal-title":"Orphanet J Rare Dis."},{"issue":"6","key":"2022112513594875400_CIT0282","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1210\/jc.2013-3826","article-title":"Acromegaly and McCune-Albright syndrome","volume":"99","author":"Salenave","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0283","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","article-title":"Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium","volume":"14","author":"Javaid","year":"2019","journal-title":"Orphanet J Rare Dis."},{"key":"2022112513594875400_CIT0284","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1750-1172-3-12","article-title":"McCune-Albright syndrome","volume":"3","author":"Dumitrescu","year":"2008","journal-title":"Orphanet J Rare Dis."},{"issue":"Suppl 1","key":"2022112513594875400_CIT0285","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/1750-1172-7-S1-S2","article-title":"Clinical guidelines for the management of craniofacial fibrous dysplasia","volume":"7","author":"Lee","year":"2012","journal-title":"Orphanet J Rare Dis."},{"issue":"2","key":"2022112513594875400_CIT0286","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/jamaoto.2017.2407","article-title":"Association of hearing loss and otologic outcomes with fibrous dysplasia","volume":"144","author":"Boyce","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"issue":"1","key":"2022112513594875400_CIT0287","doi-asserted-by":"crossref","first-page":"E126","DOI":"10.1210\/jc.2012-2111","article-title":"Optic neuropathy in McCune-Albright syndrome: effects of early diagnosis and treatment of growth hormone excess","volume":"98","author":"Boyce","year":"2013","journal-title":"J Clin Endocrinol Metab."},{"issue":"10","key":"2022112513594875400_CIT0288","doi-asserted-by":"crossref","first-page":"E2029","DOI":"10.1210\/jc.2014-1291","article-title":"McCune-Albright syndrome: a detailed pathological and genetic analysis of disease effects in an adult patient","volume":"99","author":"Vasilev","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0289","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1210\/er.2012-1013","article-title":"Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"34","author":"Beckers","year":"2013","journal-title":"Endocr Rev."},{"issue":"9","key":"2022112513594875400_CIT0290","doi-asserted-by":"crossref","first-page":"E1242","DOI":"10.1210\/jc.2015-1869","article-title":"Landscape of familial isolated and young-onset pituitary adenomas: prospective diagnosis in AIP mutation carriers","volume":"100","author":"Hernandez-Ramirez","year":"2015","journal-title":"J Clin Endocrinol Metab."},{"issue":"9","key":"2022112513594875400_CIT0291","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1210\/jc.2005-2671","article-title":"Clinical characterization of familial isolated pituitary adenomas","volume":"91","author":"Daly","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0292","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ecl.2014.10.002","article-title":"Familial isolated pituitary adenomas (FIPA) and mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene","volume":"44","author":"Daly","year":"2015","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"5777","key":"2022112513594875400_CIT0293","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1126100","article-title":"Pituitary adenoma predisposition caused by germline mutations in the AIP gene","volume":"312","author":"Vierimaa","year":"2006","journal-title":"Science."},{"issue":"5","key":"2022112513594875400_CIT0294","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1210\/jc.2006-2513","article-title":"Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families","volume":"92","author":"Daly","year":"2007","journal-title":"J Clin Endocrinol Metab."},{"issue":"11","key":"2022112513594875400_CIT0295","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0296","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1530\/ERC-15-0038","article-title":"X-linked acrogigantism syndrome: clinical profile and therapeutic responses","volume":"22","author":"Beckers","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"2022112513594875400_CIT0297","doi-asserted-by":"crossref","first-page":"4752","DOI":"10.1038\/s41467-020-18500-x","article-title":"GPR101 drives growth hormone hypersecretion and gigantism in mice via constitutive activation of Gs and Gq\/11","volume":"11","author":"Abboud","year":"2020","journal-title":"Nat Commun."},{"issue":"31","key":"2022112513594875400_CIT0298","doi-asserted-by":"crossref","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues","volume":"7","author":"Karlsson","year":"2021","journal-title":"Sci Adv."},{"issue":"1","key":"2022112513594875400_CIT0299","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1172\/JCI131609","article-title":"GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections","volume":"130","author":"Flak","year":"2020","journal-title":"J Clin Invest."},{"issue":"1","key":"2022112513594875400_CIT0300","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/me.2013-1203","article-title":"GnRH-(1-5) transactivates EGFR in Ishikawa human endometrial cells via an orphan G protein-coupled receptor","volume":"28","author":"Cho-Clark","year":"2014","journal-title":"Mol Endocrinol."},{"issue":"8","key":"2022112513594875400_CIT0301","doi-asserted-by":"crossref","first-page":"T87","DOI":"10.1530\/ERC-20-0025","article-title":"Hereditary endocrine tumours: current state-of-the-art and research opportunities: GPR101, an orphan GPCR with roles in growth and pituitary tumorigenesis","volume":"27","author":"Trivellin","year":"2020","journal-title":"Endocr Relat Cancer."},{"issue":"2","key":"2022112513594875400_CIT0302","doi-asserted-by":"crossref","first-page":"L17","DOI":"10.1530\/ERC-16-0558","article-title":"Paleogenetic study of ancient DNA suggestive of X-linked acrogigantism","volume":"24","author":"Beckers","year":"2017","journal-title":"Endocr Relat Cancer."},{"issue":"12","key":"2022112513594875400_CIT0303","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/s41574-018-0114-1","article-title":"The causes and consequences of pituitary gigantism","volume":"14","author":"Beckers","year":"2018","journal-title":"Nat Rev Endocrinol."},{"issue":"2","key":"2022112513594875400_CIT0304","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s12020-015-0804-6","article-title":"Aggressive tumor growth and clinical evolution in a patient with X-linked acro-gigantism syndrome","volume":"51","author":"Naves","year":"2016","journal-title":"Endocrine."},{"issue":"5","key":"2022112513594875400_CIT0305","doi-asserted-by":"crossref","first-page":"L37","DOI":"10.1530\/ERC-18-0065","article-title":"Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions","volume":"25","author":"Daly","year":"2018","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"2022112513594875400_CIT0306","doi-asserted-by":"crossref","first-page":"T105","DOI":"10.1530\/ERC-15-0241","article-title":"15 YEARS OF PARAGANGLIOMA: the association of pituitary adenomas and phaeochromocytomas or paragangliomas","volume":"22","author":"O\u2019Toole","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2022112513594875400_CIT0307","doi-asserted-by":"crossref","first-page":"E710","DOI":"10.1210\/jc.2014-4297","article-title":"Pituitary adenoma with paraganglioma\/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice","volume":"100","author":"Xekouki","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2022112513594875400_CIT0308","doi-asserted-by":"crossref","first-page":"e53","DOI":"10.1210\/clinem\/dgz112","article-title":"Fertility and pregnancy in women with hypopituitarism: a systematic literature review","volume":"105","author":"Vila","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0309","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nrendo.2011.38","article-title":"Management of pituitary tumors in pregnancy","volume":"7","author":"Bronstein","year":"2011","journal-title":"Nat Rev Endocrinol."},{"issue":"11","key":"2022112513594875400_CIT0310","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an Endocrine Society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0311","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-21-0462","article-title":"ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy","volume":"185","author":"Luger","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"2022112513594875400_CIT0312","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s00234-015-1519-3","article-title":"Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference","volume":"57","author":"Kreutz","year":"2015","journal-title":"Neuroradiology."},{"issue":"2","key":"2022112513594875400_CIT0313","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1172\/JCI0214264","article-title":"Functional role of estrogen in pituitary tumor pathogenesis","volume":"109","author":"Heaney","year":"2002","journal-title":"J Clin Invest."},{"issue":"2","key":"2022112513594875400_CIT0314","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2265.2010.03808.x","article-title":"Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women","volume":"73","author":"Lebbe","year":"2010","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"2022112513594875400_CIT0315","doi-asserted-by":"crossref","first-page":"R205","DOI":"10.1530\/EJE-14-0848","article-title":"Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma","volume":"172","author":"Molitch","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0316","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ecl.2019.05.004","article-title":"Pituitary tumors in pregnancy","volume":"48","author":"Huang","year":"2019","journal-title":"Endocrinol Metab Clin North Am."},{"issue":"5","key":"2022112513594875400_CIT0317","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/cen.12370","article-title":"Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients","volume":"80","author":"Domingue","year":"2014","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"2022112513594875400_CIT0318","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11102-019-01001-6","article-title":"Magnetic resonance imaging inthe management of prolactinomas; a review of the evidence","volume":"23","author":"Varlamov","year":"2020","journal-title":"Pituitary."},{"issue":"2","key":"2022112513594875400_CIT0319","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","article-title":"Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas","volume":"65","author":"Casanueva","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"10","key":"2022112513594875400_CIT0320","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1210\/jc.2009-2331","article-title":"Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women","volume":"95","author":"Caron","year":"2010","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0321","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev."},{"issue":"6","key":"2022112513594875400_CIT0322","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/cen.14097","article-title":"Gestational diabetes and acromegaly: single-centre experience of 14 pregnancies","volume":"91","author":"Vialon","year":"2019","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2022112513594875400_CIT0323","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1007\/s11102-018-0910-6","article-title":"Pregnancy-associated Cushing\u2019s disease? An exploratory retrospective study","volume":"21","author":"Palejwala","year":"2018","journal-title":"Pituitary."},{"issue":"4","key":"2022112513594875400_CIT0324","doi-asserted-by":"crossref","first-page":"E658","DOI":"10.1210\/jc.2010-2235","article-title":"Pregnancy does not accelerate corticotroph tumor progression in Nelson\u2019s syndrome","volume":"96","author":"Jornayvaz","year":"2011","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0325","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12020-016-1117-0","article-title":"Cushing\u2019s syndrome and pregnancy outcomes: a systematic review of published cases","volume":"55","author":"Caimari","year":"2017","journal-title":"Endocrine."},{"issue":"6","key":"2022112513594875400_CIT0326","doi-asserted-by":"crossref","first-page":"R259","DOI":"10.1530\/EJE-17-1058","article-title":"Management of endocrine disease: management of Cushing\u2019s syndrome during pregnancy: solved and unsolved questions","volume":"178","author":"Brue","year":"2018","journal-title":"Eur J Endocrinol."},{"issue":"3","key":"2022112513594875400_CIT0327","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/EJE-20-1224","article-title":"Pre-term birth in women exposed to Cushing\u2019s disease: the Baby-Cush study","volume":"184","author":"Hochman","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022112513594875400_CIT0328","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/AOG.0000000000001747","article-title":"Macroprolactinomas and nonfunctioning pituitary adenomas and pregnancy outcomes","volume":"129","author":"Lambert","year":"2017","journal-title":"Obstet Gynecol."},{"issue":"2","key":"2022112513594875400_CIT0329","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s11102-020-01107-2","article-title":"Management of sellar and parasellar tumors becoming symptomatic during pregnancy: a practical algorithm based on multi-center experience and systematic literature review","volume":"24","author":"Zoli","year":"2021","journal-title":"Pituitary."},{"issue":"1","key":"2022112513594875400_CIT0330","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1530\/EJE-21-0145","article-title":"Apoplexy of microprolactinomas during pregnancy: report of five cases and review of the literature","volume":"185","author":"Kuhn","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"9","key":"2022112513594875400_CIT0331","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/nrendo.2009.147","article-title":"Nonfunctioning pituitary adenomas: the Oxford experience","volume":"5","author":"Wass","year":"2009","journal-title":"Nat Rev Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0332","doi-asserted-by":"crossref","first-page":"bvaa021","DOI":"10.1210\/jendso\/bvaa021","article-title":"Presenting features in 269 patients with clinically nonfunctioning pituitary adenomas enrolled in a prospective study","volume":"4","author":"Freda","year":"2020","journal-title":"J Endocr Soc."},{"issue":"5","key":"2022112513594875400_CIT0333","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1007\/s11102-019-00982-8","article-title":"Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients","volume":"22","author":"Pappy","year":"2019","journal-title":"Pituitary."},{"issue":"5","key":"2022112513594875400_CIT0334","doi-asserted-by":"crossref","first-page":"R231","DOI":"10.1530\/EJE-17-0154","article-title":"Management of endocrine disease: risk of overtreatment in patients with adrenal insufficiency: current and emerging aspects","volume":"177","author":"Mazziotti","year":"2017","journal-title":"Eur J Endocrinol."},{"issue":"6","key":"2022112513594875400_CIT0335","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1530\/EJE-14-0097","article-title":"Association between l-thyroxine treatment, GH deficiency, and radiological vertebral fractures in patients with adult-onset hypopituitarism","volume":"170","author":"Mazziotti","year":"2014","journal-title":"Eur J Endocrinol."},{"issue":"1","key":"2022112513594875400_CIT0336","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/jc.2013-2394","article-title":"Cardiovascular risk in adult patients with growth hormone (GH) deficiency and following substitution with GH--an update","volume":"99","author":"Gazzaruso","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0337","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12020-015-0738-z","article-title":"Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency","volume":"52","author":"Mazziotti","year":"2016","journal-title":"Endocrine."},{"issue":"1","key":"2022112513594875400_CIT0338","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s12020-016-1159-3","article-title":"Mortality in adults with hypopituitarism: a systematic review and meta-analysis","volume":"56","author":"Jasim","year":"2017","journal-title":"Endocrine."},{"issue":"4","key":"2022112513594875400_CIT0339","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2265.2011.04068.x","article-title":"Pituitary apoplexy in non-functioning pituitary adenomas: long term follow up is important because of significant numbers of tumour recurrences","volume":"75","author":"Pal","year":"2011","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"3","key":"2022112513594875400_CIT0340","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2015-3653","article-title":"Pituitary medicine from discovery to patient-focused outcomes","volume":"101","author":"Melmed","year":"2016","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022112513594875400_CIT0341","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1210\/jc.2014-3595","article-title":"The year in pituitary 2014","volume":"99","author":"Ho","year":"2014","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0342","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1093\/qjmed\/hcr221","article-title":"Acute shrinkage of a giant prolactinoma, masquerading as an erosive skull base tumour, with cabergoline","volume":"106","author":"Dash","year":"2013","journal-title":"QJM."},{"issue":"1","key":"2022112513594875400_CIT0343","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ecl.2007.10.013","article-title":"Hyperprolactinemia and prolactinomas","volume":"37","author":"Mancini","year":"2008","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"8","key":"2022112513594875400_CIT0344","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40618-020-01478-0","article-title":"Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study","volume":"44","author":"Beccuti","year":"2021","journal-title":"J Endocrinol Invest."},{"key":"2022112513594875400_CIT0345","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000486000","article-title":"Metabolic syndrome in hyperprolactinemia","volume":"49","author":"Andersen","year":"2018","journal-title":"Front Horm Res."},{"issue":"1","key":"2022112513594875400_CIT0346","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12902-021-00733-6","article-title":"Adverse body composition and lipid parameters in patients with prolactinoma: a case-control study","volume":"21","author":"Posawetz","year":"2021","journal-title":"BMC Endocr Disord."},{"issue":"3","key":"2022112513594875400_CIT0347","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s11102-020-01041-3","article-title":"Hyperprolactinemia and bone","volume":"23","author":"di Filippo","year":"2020","journal-title":"Pituitary."},{"issue":"3","key":"2022112513594875400_CIT0348","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1007\/s12020-011-9462-5","article-title":"Vertebral fractures in males with prolactinoma","volume":"39","author":"Mazziotti","year":"2011","journal-title":"Endocrine."},{"issue":"4","key":"2022112513594875400_CIT0349","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11102-011-0293-4","article-title":"High prevalence of radiological vertebral fractures in women with prolactin-secreting pituitary adenomas","volume":"14","author":"Mazziotti","year":"2011","journal-title":"Pituitary."},{"issue":"1","key":"2022112513594875400_CIT0350","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11102-020-01084-6","article-title":"Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study","volume":"24","author":"Oh","year":"2021","journal-title":"Pituitary."},{"issue":"1","key":"2022112513594875400_CIT0351","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41572-019-0071-6","article-title":"Acromegaly","volume":"5","author":"Colao","year":"2019","journal-title":"Nat Rev Dis Primers."},{"issue":"6","key":"2022112513594875400_CIT0352","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1530\/EJE-20-0019","article-title":"Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality","volume":"182","author":"Esposito","year":"2020","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0353","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord."},{"issue":"8","key":"2022112513594875400_CIT0354","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/BF03346423","article-title":"Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study","volume":"31","author":"Giustina","year":"2008","journal-title":"J Endocrinol Invest."},{"issue":"6","key":"2022112513594875400_CIT0355","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/ERC-16-0106","article-title":"Mortality in acromegaly: a 20-year follow-up study","volume":"23","author":"Ritvonen","year":"2016","journal-title":"Endocr Relat Cancer."},{"key":"2022112513594875400_CIT0356","doi-asserted-by":"crossref","first-page":"577173","DOI":"10.3389\/fendo.2020.577173","article-title":"Hypertension in acromegaly in relationship to biochemical control and mortality: global ACROSTUDY outcomes","volume":"11","author":"Vila","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"7","key":"2022112513594875400_CIT0357","doi-asserted-by":"crossref","first-page":"3294","DOI":"10.1210\/en.2008-0143","article-title":"Epithelial sodium channel is a key mediator of growth hormone-induced sodium retention in acromegaly","volume":"149","author":"Kamenicky","year":"2008","journal-title":"Endocrinology."},{"issue":"2","key":"2022112513594875400_CIT0358","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1210\/er.2013-1071","article-title":"Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications","volume":"35","author":"Kamenicky","year":"2014","journal-title":"Endocr Rev."},{"issue":"6","key":"2022112513594875400_CIT0359","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1210\/jc.2018-00325","article-title":"Persistence of diabetes and hypertension after multimodal treatment of acromegaly","volume":"103","author":"Gonzalez","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"3-4","key":"2022112513594875400_CIT0360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ando.2020.03.010","article-title":"Cardiovascular complications of acromegaly","volume":"82","author":"Kamenicky","year":"2021","journal-title":"Ann Endocrinol (Paris)."},{"issue":"5","key":"2022112513594875400_CIT0361","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1530\/EJE-09-0945","article-title":"Acromegaly per se does not increase the risk for coronary artery disease","volume":"162","author":"Akutsu","year":"2010","journal-title":"Eur J Endocrinol."},{"issue":"15","key":"2022112513594875400_CIT0362","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/S0002-9149(99)80721-8","article-title":"Cardiopulmonary performance during exercise in acromegaly, and the effects of acute suppression of growth hormone hypersecretion with octreotide","volume":"75","author":"Giustina","year":"1995","journal-title":"Am J Cardiol."},{"issue":"1","key":"2022112513594875400_CIT0363","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eem.11.82","article-title":"Sleep apnea in acromegaly: a review on prevalence, pathogenetic aspects and treatment","volume":"7","author":"Davi","year":"2012","journal-title":"Expert Rev Endocrinol Metab."},{"key":"2022112513594875400_CIT0364","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.sleep.2021.01.033","article-title":"Impact of obstructive sleep apnea on cardiovascular risk in patients with acromegaly","volume":"80","author":"Cao","year":"2021","journal-title":"Sleep Med."},{"issue":"5","key":"2022112513594875400_CIT0365","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1530\/EJE-08-0442","article-title":"Sleep apnoea syndrome is highly prevalent in acromegaly and only partially reversible after biochemical control of the disease","volume":"159","author":"Davi","year":"2008","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"2022112513594875400_CIT0366","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1007\/s00701-021-04846-8","article-title":"Prevalence and outcome of comorbidities associated with acromegaly","volume":"163","author":"Berkmann","year":"2021","journal-title":"Acta Neurochir (Wien)."},{"issue":"2","key":"2022112513594875400_CIT0367","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s11102-020-01092-6","article-title":"HOMA-IR in acromegaly: a systematic review and meta-analysis","volume":"24","author":"Biagetti","year":"2021","journal-title":"Pituitary."},{"issue":"7","key":"2022112513594875400_CIT0368","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.tem.2016.04.014","article-title":"Current and emerging aspects of diabetes mellitus in acromegaly","volume":"27","author":"Frara","year":"2016","journal-title":"Trends Endocrinol Metab."},{"issue":"3","key":"2022112513594875400_CIT0369","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1007\/s12020-021-02711-3","article-title":"Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant","volume":"73","author":"Chiloiro","year":"2021","journal-title":"Endocrine."},{"issue":"1","key":"2022112513594875400_CIT0370","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000375450","article-title":"Bone and joint disorders in acromegaly","volume":"103","author":"Claessen","year":"2016","journal-title":"Neuroendocrinology."},{"issue":"2","key":"2022112513594875400_CIT0371","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1530\/EJE-20-0530","article-title":"Carpal tunnel syndrome in acromegaly: a nationwide study","volume":"184","author":"Vouzouneraki","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"4","key":"2022112513594875400_CIT0372","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.tem.2020.01.011","article-title":"Acromegaly and vertebral fractures: facts and questions","volume":"31","author":"Giustina","year":"2020","journal-title":"Trends Endocrinol Metab."},{"issue":"4","key":"2022112513594875400_CIT0373","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1210\/er.2018-00005","article-title":"Pituitary diseases and bone","volume":"39","author":"Mazziotti","year":"2018","journal-title":"Endocr Rev."},{"issue":"3","key":"2022112513594875400_CIT0374","doi-asserted-by":"crossref","first-page":"dgz054","DOI":"10.1210\/clinem\/dgz054","article-title":"Effects of pegvisomant and pasireotide LAR on vertebral fractures in acromegaly resistant to first-generation SRLs","volume":"105","author":"Chiloiro","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"12","key":"2022112513594875400_CIT0375","first-page":"3487","article-title":"Incidence of benign and malignant tumors in patients with acromegaly is increased: a nationwide population-based study","volume":"106","author":"Esposito","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2022112513594875400_CIT0376","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s42000-020-00235-5","article-title":"Clinical presentation and management of acromegaly in elderly patients","volume":"20","author":"Ceccato","year":"2021","journal-title":"Hormones (Athens)."},{"issue":"11-12","key":"2022112513594875400_CIT0377","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1159\/000505332","article-title":"Natural history of acromegaly: incidences, re-operations, cancers, and mortality rates in a national cohort","volume":"110","author":"Wu","year":"2020","journal-title":"Neuroendocrinology."},{"issue":"1","key":"2022112513594875400_CIT0378","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/cen.14468","article-title":"Insulin-like growth factor-1, growth hormone and disease outcomes in acromegaly: a population study","volume":"95","author":"Thomas","year":"2021","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"12","key":"2022112513594875400_CIT0379","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"2022112513594875400_CIT0380","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2147\/TCRM.S12952","article-title":"Treatment of Cushing disease: overview and recent findings","volume":"6","author":"Mancini","year":"2010","journal-title":"Ther Clin Risk Manag."},{"issue":"5","key":"2022112513594875400_CIT0381","doi-asserted-by":"crossref","first-page":"e2035","DOI":"10.1210\/clinem\/dgab058","article-title":"Acute and life-threatening complications in Cushing syndrome: prevalence, predictors, and mortality","volume":"106","author":"Schernthaner-Reiter","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0382","doi-asserted-by":"crossref","first-page":"bvz033","DOI":"10.1210\/jendso\/bvz033","article-title":"Hypercoagulability in Cushing Syndrome, prevalence of thrombotic events: a large, single-center, retrospective study","volume":"4","author":"Suarez","year":"2020","journal-title":"J Endocr Soc."},{"issue":"4","key":"2022112513594875400_CIT0383","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"van der Pas","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0384","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1210\/jc.2011-3123","article-title":"Body composition and cardiovascular risk markers after remission of Cushing\u2019s disease: a prospective study using whole-body MRI","volume":"97","author":"Geer","year":"2012","journal-title":"J Clin Endocrinol Metab."},{"issue":"5","key":"2022112513594875400_CIT0385","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrendo.2013.5","article-title":"Glucocorticoids and the regulation of growth hormone secretion","volume":"9","author":"Mazziotti","year":"2013","journal-title":"Nat Rev Endocrinol."},{"issue":"5","key":"2022112513594875400_CIT0386","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11892-017-0860-9","article-title":"Diabetes in Cushing disease","volume":"17","author":"Mazziotti","year":"2017","journal-title":"Curr Diab Rep."},{"key":"2022112513594875400_CIT0387","doi-asserted-by":"crossref","first-page":"600323","DOI":"10.3389\/fendo.2020.600323","article-title":"Lipid abnormalities in patients with Cushing\u2019s disease and its relationship with impaired glucose metabolism","volume":"11","author":"Sun","year":"2020","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2022112513594875400_CIT0388","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","article-title":"Clinical relevance of cardiac structure and function abnormalities in patients with Cushing\u2019s syndrome before and after cure","volume":"76","author":"Toja","year":"2012","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"2022112513594875400_CIT0389","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s11102-005-1051-2","article-title":"Cushing\u2019s syndrome and bone","volume":"7","author":"Mancini","year":"2004","journal-title":"Pituitary."},{"issue":"4","key":"2022112513594875400_CIT0390","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bone.2003.11.026","article-title":"Perspectives on glucocorticoid-induced osteoporosis","volume":"34","author":"Canalis","year":"2004","journal-title":"Bone."},{"issue":"2","key":"2022112513594875400_CIT0391","doi-asserted-by":"crossref","first-page":"101515","DOI":"10.1016\/j.beem.2021.101515","article-title":"Osteopathy in mild adrenal Cushing\u2019s syndrome and Cushing disease","volume":"35","author":"Frara","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"12","key":"2022112513594875400_CIT0392","doi-asserted-by":"crossref","first-page":"e4490","DOI":"10.1210\/clinem\/dgaa625","article-title":"Persisting muscle dysfunction in Cushing\u2019s syndrome despite biochemical remission","volume":"105","author":"Vogel","year":"2020","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2022112513594875400_CIT0393","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1530\/EJE-20-1285","article-title":"Patients with low IGF-I after curative surgery for Cushing\u2019s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy","volume":"184","author":"Vogel","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"9","key":"2022112513594875400_CIT0394","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.tem.2020.04.004","article-title":"The immune system in Cushing\u2019s syndrome","volume":"31","author":"Hasenmajer","year":"2020","journal-title":"Trends Endocrinol Metab."},{"issue":"2","key":"2022112513594875400_CIT0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s11154-021-09670-0","article-title":"Endocrine risk factors for COVID-19: endogenous and exogenous glucocorticoid excess","volume":"23","author":"Vogel","year":"2022","journal-title":"Rev Endocr Metab Disord."},{"issue":"3","key":"2022112513594875400_CIT0396","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s11102-021-01148-1","article-title":"COVID-19 and the pituitary","volume":"24","author":"Frara","year":"2021","journal-title":"Pituitary."},{"issue":"2","key":"2022112513594875400_CIT0397","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/joim.13056","article-title":"Psychiatric and neurocognitive consequences of endogenous hypercortisolism","volume":"288","author":"Piasecka","year":"2020","journal-title":"J Intern Med."},{"issue":"3","key":"2022112513594875400_CIT0398","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1055\/a-1197-6380","article-title":"Mortality of patients with Cushing\u2019s disease","volume":"129","author":"Ntali","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes."},{"issue":"1","key":"2022112513594875400_CIT0399","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1210\/clinem\/dgaa774","article-title":"Diabetes, active disease, and afternoon serum cortisol levels predict Cushing\u2019s disease mortality: a cohort study","volume":"106","author":"Roldan-Sarmiento","year":"2021","journal-title":"J Clin Endocrinol Metab."},{"issue":"7","key":"2022112513594875400_CIT0400","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","article-title":"Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study","volume":"4","author":"Clayton","year":"2016","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"2022112513594875400_CIT0401","doi-asserted-by":"crossref","first-page":"R65","DOI":"10.1530\/EJE-21-0162","article-title":"Endocrine tumours: thyrotropin-secreting pituitary adenoma: a structured review of 535 adult cases","volume":"185","author":"De Herdt","year":"2021","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"2022112513594875400_CIT0402","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1507\/endocrj.EJ20-0707","article-title":"Preoperative and long-term efficacy and safety of lanreotide autogel in patients with thyrotropin-secreting pituitary adenoma: a multicenter, single-arm, phase 3 study in Japan","volume":"68","author":"Shimatsu","year":"2021","journal-title":"Endocr J."},{"issue":"5","key":"2022112513594875400_CIT0403","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1007\/s11102-021-01154-3","article-title":"Thyrotropin-secreting pituitary adenomas induce left atrial enlargement with subclinical atrial fibrillation: an echocardiographic study","volume":"24","author":"Yoshiki","year":"2021","journal-title":"Pituitary."},{"issue":"9","key":"2022112513594875400_CIT0404","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1210\/js.2018-00091","article-title":"High prevalence of radiological vertebral fractures in patients with TSH-secreting pituitary adenoma","volume":"2","author":"Frara","year":"2018","journal-title":"J Endocr Soc."},{"issue":"2","key":"2022112513594875400_CIT0405","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1530\/ERC-16-0432","article-title":"Thyroid nodules and cancer management guidelines","volume":"24","author":"Nabhan","year":"2017","journal-title":"Endocr Relat Cancer"},{"issue":"Suppl 1","key":"2022112513594875400_CIT0406","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000080731","article-title":"Epidemiology of neuroendocrine tumours","volume":"80","author":"Taal","year":"2004","journal-title":"Neuroendocrinology."}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnac010\/43622940\/bnac010.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/43\/6\/1003\/47266106\/bnac010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/43\/6\/1003\/47266106\/bnac010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T15:33:37Z","timestamp":1700408017000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/43\/6\/1003\/6565598"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,8]]},"references-count":406,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,4,8]]},"published-print":{"date-parts":[[2022,11,25]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnac010","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,1]]},"published":{"date-parts":[[2022,4,8]]}}}